CCS
ANGO icon

Crosspoint Capital Strategies’s AngioDynamics ANGO Stock Holding History

Crosspoint Capital Strategies’s Portfolio ANGO Stock Details ANGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,400
Closed -$22K – 510
2014
Q1 		$22K Buy
+1,400
New +$22.8K 0.01% 354

Other funds holding ANGO

RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Crosspoint Capital Strategies's ANGO Position: Q2 2014 in Review

Crosspoint Capital Strategies sold out of AngioDynamics (ANGO) in Q2 2014, closing a stake of 1,400 shares — an estimated $22K sold.

Crosspoint Capital Strategies first reported a position in ANGO in Q1 2014 and held it in 1 quarter. The position peaked at $22K in Q1 2014. 109 funds tracked by Wall St. Rank hold ANGO as of Q2 2014.

  • Crosspoint Capital Strategies reported no remaining AngioDynamics position as of Q2 2014 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 1,400 AngioDynamics shares in Q2 2014, an estimated $22K.
  • Crosspoint Capital Strategies first reported a position in AngioDynamics in Q1 2014 and held it in 1 quarter.
  • Crosspoint Capital Strategies's AngioDynamics position peaked at $22K in Q1 2014.
  • 109 funds tracked by Wall St. Rank held AngioDynamics as of Q2 2014.

Based on Crosspoint Capital Strategies's 13F filing for Q2 2014, filed 29 Jul 2014.